Physician profile
Ashraf Mostafa
NPI 1396976080
$4,712.40
in general payments reported to CMS, 2019-2025
30 companies · $2,058 in 2025
The $2,058 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $93.42 · 2021: $437 · 2022: $329 · 2023: $903 · 2024: $464 · 2025: $2,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955 · Travel and Lodging: $1,382 · Education: $87.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.82 |
| Travel and Lodging | $1,382.16 |
| Education | $87.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,807.52 | 2025 | Xience Skypoint, Jot Dx |
| Novartis Pharmaceuticals Corporation | $345.69 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $288.97 | 2021-2024 | Farxiga |
| Tactile Systems Technology INC | $258.54 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Boston Scientific Corporation | $221.66 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $215.26 | 2019-2025 | Lifevest |
| Avinger INC. | $207.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.41 | 2021-2025 | Jardiance |
| Medtronic, INC. | $165.24 | 2023-2025 | Corevalve Evolut R, Venaseal, Reveal Linq |
| Amgen INC. | $163.13 | 2019-2023 | Repatha |
| Abiomed | $146.65 | 2023 | Impella |
| Janssen Pharmaceuticals, INC | $138.84 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $121.26 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.21 | 2023-2024 | Camzyos |
| Pfizer INC. | $81.44 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $38.41 | 2021-2022 | |
| Irhythm Technologies, INC. | $30.56 | 2022-2023 | Zio Xt Patch |
| United Therapeutics Corporation | $27.70 | 2025 | Tyvaso |
| Kestra Medical Technology Services, INC. | $24.08 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals, LTD. | $21.50 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $20.37 | 2024 | Arcalyst |
| Chiesi USA, INC. | $16.39 | 2019 | |
| Cardiovascular Systems INC. | $15.74 | 2023 | Diamondback Peripheral |
| Philips North America LLC | $15.29 | 2024 | (Ck4) Mcot |
| Cardiva Medical, INC. | $14.90 | 2021 | |
| Edwards Lifesciences Corporation | $14.58 | 2019 | |
| Baxter Healthcare | $13.77 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Electromed, INC. | $13.57 | 2022 | |
| Sobi, INC | $12.11 | 2021 | |
| Bardy Diagnostics, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashraf Mostafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.